Skip to content

Comparative Evaluation of Free Gingival Graft (FGG) and Porcine-Derived Absorbable Collagen Matrix Membrane (MS) as Sealing Materials for Site Preservation in the Maxillary Anterior Region

Comparative Evaluation of Free Gingival Graft (FGG) and Porcine-Derived Absorbable Collagen Matrix Membrane (MS) as Sealing Materials for Site Preservation in the Maxillary Anterior Region

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500114825
Enrollment
Unknown
Registered
2025-12-17
Start date
2024-11-26
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

none

Interventions

Experimental Group: Porcine-derived Absorbable Collagen Matrix Membrane :The experimental group used porcine-derived absorbable collagen matrix membrane as the ridge preservation material.
Control Group: Autologous Free Gingival Graft Group :The control group used autologous free gingival graft as the ridge preservation material.

Sponsors

Department of Stomatology, General Hospital of Northern Theater Command, People's Liberation Army
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: (1) Patients aged 18 to 60 years, regardless of gender; (2) Non-restorable teeth in the maxillary anterior and premolar regions; (3) Post-extraction buccal/palatal bone plate loss <50%; (4) Insufficient residual bone volume for immediate implant placement; (5) Adjacent teeth with good periodontal condition and no attachment loss.

Exclusion criteria

Exclusion criteria: Exclusion criteria: (1) Refusal to sign informed consent; (2) Patients with acute apical periodontitis or acute periodontitis that may interfere with treatment outcomes; (3) Significant local or systemic infections; (4) Severe cardiovascular diseases; (5) Severe allergic predisposition; (6) Poorly controlled diabetes mellitus (e.g., HbA1c >7%); (7) Uncontrolled systemic diseases (such as hypertension); (8) Heavy smoking (>10 cigarettes per day); (9) Patients receiving bisphosphonates via intramuscular or intravenous administration; (10) History of radiotherapy or chemotherapy; (11) Current participation in other clinical trials or having completed a clinical trial within the past six weeks; (12) Mental incompetence or inability to understand study requirements; (13) Pregnancy, lactation, or plans for pregnancy; (14) Poor compliance or unwillingness to attend follow-up visits; (15) Patients deemed unsuitable by investigators for participation.

Design outcomes

Primary

MeasureTime frame
The change in bone width at 3 mm from the alveolar crest.;

Secondary

MeasureTime frame
The change in bone width at 1 mm and 5mm from the alveolar crest.;Change in width of keratinized gingiva; Wound healing rate;Visual Analogue Scale score;the time of the surgery;The change in thickness at 2 mm below the lowest point of the gingival margin;Alveolar bone width at 1 mm, 3 mm, and 5 mm below the alveolar crest.;

Countries

China

Contacts

Public ContactYulong Tang

Department of Stomatology, General Hospital of Northern Theater Command, People's Liberation Army of China

tangyulong2009@foxmail.com+86 153 0988 9050

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026